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Abstract
Background: In the current context of personalized medicine, one of the major challenges in the management of
rheumatoid arthritis (RA) is to identify biomarkers that predict drug responsiveness. From the European APPRAISE
trial, our main objective was to identify a gene expression profile associated with responsiveness to abatacept
(ABA) + methotrexate (MTX) and to understand the involvement of this signature in the pathophysiology of RA.
Methods: Whole human genome microarrays (4 × 44 K) were performed from a first subset of 36 patients with RA.
Data validation by quantitative reverse-transcription (qRT)-PCR was performed from a second independent subset
of 32 patients with RA. Gene Ontology and WikiPathways database allowed us to highlight the specific biological
mechanisms involved in predicting response to ABA/MTX.
Results: From the first subset of 36 patients with RA, a combination including 87 transcripts allowed almost perfect
separation between responders and non-responders to ABA/MTX. Next, the second subset of patients 32 with RA
allowed validation by qRT-PCR of a minimal signature with only four genes. This latter signature categorized 81% of
patients with RA with 75% sensitivity, 85% specificity and 85% negative predictive value. This combination showed
a significant enrichment of genes involved in electron transport chain (ETC) pathways. Seven transcripts from ETC
pathways (NDUFA6, NDUFA4, UQCRQ, ATP5J, COX7A2, COX7B, COX6A1) were significantly downregulated in
responders versus non-responders to ABA/MTX. Moreover, dysregulation of these genes was independent of
inflammation and was specific to ABA response.
Conclusion: Pre-silencing of ETC genes is associated with future response to ABA/MTX and might be a crucial key
to susceptibility to ABA response.
Keywords: Biomarkers, Rheumatoid arthritis, Abatacept, Microarray, Abatacept response, Oxydative stress,
Mitochondria
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Background
Recent advances in our understanding of the patho-
physiology of rheumatoid arthritis (RA) have led to the
development of new biologic treatments designed to
act against a precise therapeutic target: these include
tumor necrosis factor-alpha (TNFα), interleukin-1-receptor
antagonist (IL1-Ra, anakinra), cytotoxic T-lymphocyte-
associated protein 4 (CTLA4-Ig or abatacept (ABA)), CD20
expressed on B cells (rituximab) and IL-6 receptor (toci-
lizumab) [1]. All these biologic agents have proven efficacy
in stopping joint inflammation and structural damage in
association with the anchor drug methotrexate (MTX) [1].
No one molecule has proven its clinical superiority over
others in terms of efficacy [2–6]. In addition, no response
to these treatments is obtained in approximately 30% of pa-
tients with RA, and the response to all these medications is
highly variable from one patient to another. Nevertheless,
prescription of biologics agents remains highly empirical
[7–9]. Presently, we are still unable to predict the clinical
efficacy of these treatments in a given patient because of
the heterogeneity of RA and the subgroups of patients
susceptible to responding better to one molecule than to
another. Given the increasing number of available mole-
cules, it is crucial to identify predictive markers in order
to optimize drug prescription only to those patients sus-
ceptible to responding and thus avoiding side effects.
In the current context of personalized medicine,
large-scale analysis of gene expression to predict drug
response is a relevant and original approach, which has
already shown its utility in cancer or kidney transplant-
ation [10–12]. Gene expression profiling is clearly a
powerful method for the identification of biomarkers
and the development of personalized medicine in the
field of rheumatology [13–16]. This approach has
already allowed us to identify and validate two gene
combinations able to predict response to infliximab or
anakinra although in small cohorts of patients with RA
[17, 18]. The proof of concept of gene expression pro-
files or signatures as a predictor of good response to
drugs in RA was further confirmed by other teams
using other biologic agents, but in cohorts that in-
cluded very few patients with RA [19–21]. Thus, we
conducted this present ancillary study as a follow-up to
the APPRAISE trial [22, 23]. Our main objective was to
identify and validate a gene expression profile associ-
ated with a good response to ABA/MTX, and to under-
stand the involvement of this signature in RA
pathophysiology.
Methods
Patients from the APPRAISE trial
A total of 68 patients with RA from the APPRAISE trial
were enrolled in this ancillary study [22, 23]. The AP-
PRAISE study assessed the capability of the composite
power of Doppler and greyscale ultrasound score to meas-
ure the early effect and time course of response to treat-
ment with ABA in biologic-naïve patients with active RA
despite MTX therapy. APPRAISE (NCT00767325) ini-
tially including 104 patients with RA was a 24-week,
Phase IIIb, open-label, multicenter, single-arm study con-
ducted at 21 sites across Europe (Denmark, France,
Germany, Hungary, Italy, Norway, Spain and the UK) [22,
23]. Eligible patients were ≥18 years of age, had American
College of Rheumatology (ACR)-defined RA according to
the 1987 classification criteria for at least 6 months [24],
and had been on MTX (≥15 mg/week) for at least
3 months prior to baseline, with a stable MTX dose for
at least 28 days before baseline (except in cases of in-
tolerance to MTX). Patients were required to have ac-
tive disease, defined by a baseline disease activity score
in 28 joints (calculated with C-reactive protein (CRP))
(DAS28(CRP)) >3.2 or tender and ≥6 swollen joint
counts, and CRP above the upper limit of normal. All
patients received intravenous (IV) infusions of ABA at
a weight-titered dose of 10 mg/kg at baseline (day 1),
and at weeks 2, 4, 8, 12, 16, 20 and 24, in addition to
stable doses of concomitant MTX (≥15 mg/week).
MTX dose increases were not permitted, and dose de-
creases were allowed only in cases of intolerance. Oral
corticosteroid use (stable dose of ≤10 mg prednisone/
day) was permitted during the study. For this study,
5 ml of whole blood was collected in PAXgene RNA
tube (PreAnalytiX, Qiagen) just before the first infusion
and 6 months later and was stored at –80 °C until use.
Clinical evaluation and response to ABA/MTX
Several clinical characteristics were collected at baseline
and 6 months later: age, gender, disease duration and
MTX and corticosteroid doses. Disease activity was evalu-
ated at all assessment visits (baseline, weeks 1, 2, 4, 6, 8,
12, 16, 20 and 24) using the DAS28(CRP) calculated from
28 tender joints, 28 swollen joints, CRP and patient global
assessment (visual analog scale (VAS); 0–10 scale).
The response to ABA/MTX was evaluated at 6 months
using European League Against Rheumatism (EULAR)
response criteria based on DAS28(CRP) [25]. Since we
were looking for biomarkers associated with good re-
sponse to ABA/MTX, patients were categorized according
to their EULAR response as responders (R) (n = 36) or
non-responders (NR) (comprising moderate responders
(n = 25) and no responders (n = 7)) [25].
RNA preparation
Total RNAs from whole blood were extracted with PAX-
gene blood RNA kit according to the manufacturer’s rec-
ommendations (Qiagen PreAnalytiX GmbH, Courtaboeuf,
France) and stored at –80 °C until use. Total RNA from
10 healthy donors (5 women and 5 men) was pooled and
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used as an internal standard reference (control pool). The
quality and quantity of isolated mRNAs were assessed
using the 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA) and the Nanodrop device (Thermo
Scientific, Wilmington, USA). Only RNA samples with a
minimal RNA integrity number of 7 were used for subse-
quent experiments.
Microarrays
Whole human genomic DNA microarrays were used to
analyze two-colored gene expression profiling (4 × 44 K
Whole Human Genome, Agilent Technologies, Les
Ulis, France). Each RNA sample from patients with RA
was labeled by Cyanine-5 and co-hybridized with a
Cyanine-3 labeled RNA control pool according to the
manufacturer’s instructions (Low Input QuickAmp
Labeling Kit, Agilent Technologies, Les Ulis, France).
Briefly, 100 ng of RNAs were labeled with cyanine-5
CTP (patients with RA) or cyanine-3 CTP (control pool).
After hybridization reaction using a hybridization kit (Agi-
lent Technologies, Les Ulis, France) co-hybridization was
performed at 65 °C for 17 hours. After wash steps, the mi-
croarrays were scanned with a 5-μM pixel size using the
DNA Microarray Scanner GB (Agilent Technologies, Les
Ulis, France). Image analysis and extraction of raw and
normalized signal intensities (lowess) were performed
using Feature Extraction Software 10.5.1.1 (Agilent Tech-
nologies). The data were in agreement with the guidelines
for minimum information about a microarray experiment
and were deposited in the database of the National Center
for Biotechnology Information Gene Expression Omnibus
(https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE68215). The data are accessible
[GEO:GSE68215]. Non-uniform spots and saturated spots
or spots with intensities below the background were not
taken into account. Only spots that passed these quality
controls on 100% of arrays were selected for further ana-
lysis. Hierarchical clustering was performed using the
Pearson coefficient metric and complete linkage to build
the transcripts and sample dendrograms.
Quantitative reverse transcription-PCR (qRT-PCR)
cDNA was synthesized from 1-μg RNA samples using
random primers and M-MLV enzyme (Invitrogen™,
Carlsbad, USA). qRT-PCR was performed using a Light-
cycler as instructed by the manufacturer (Roche™, Meylan,
France). qRT-PCR reactions were performed for each
sample in duplicate using SYBR-Green (Roche™, Meylan,
France) and values were normalized using the geometric
mean of three control genes (18S, ACTB, B2M) defined by
the geNorm algorithm [26]. Sequences of primers (Euro-
gentec™, Fremont, USA) used for qRT-PCR were: BLOC1S1
forward, 5’-AAGCAGACAGGCCAGTGGAT-3’; BLOC1S1
reverse, 5’-CAGTGCAGTGGCAATGGTG-3’; RNASE3
forward, 5’-CAGGAGCCACAGCTCAGAGA-3’; RNASE3
reverse, 5’-GAGCCCTCCACACCCATAAG-3’; COX6A1
forward, 5’-CCACTTCCAACTGGCTACGA-3’; COX6A1
reverse, 5’-AAGCAAAGGGATGGGAGACC-3’; PTRH2
forward, 5’-GCTGTTGGAGTTGCTTGTGG-3’; PTRH2
reverse, 5’-AGGCTGAAACAGCAGCATGA-3’; 18S for-
ward, 5’-GTGGAGCGATTTGTCTGGTT-3’; 18S reverse,
5’-CGCTGAGCCAGTCAGTGTAG-3’; ACTB forward, 5’-
CTGGAACGGTGAAGGTGACA-3’; ACTB reverse, 5’-AA
GGGACTTCCTGTAACAATGCA-3’; B2M forward, 5’-T
GCTGTCTCCATGTTTGATGTATCT-3’; B2M reverse,
5’-TCTCTGCTCCCCACCTCTAAGT-3’.
Statistical and functional analysis
Comparisons of clinical and biological data between R
and NR were performed at baseline using Student’s t test
for continuous variables. Comparisons of R or NR before
and after treatment were performed using the paired t
test. Identification of clinical parameters able to predict
good response to ABA/MTX was performed in two dif-
ferent multivariate analyses: (1) a logistic regression
model with variable selection using Bayesian information
criterion (BIC) and (2) linear discriminant analysis (LDA),
which estimates a coefficient for each variable.
Data from transcriptomic analysis were analyzed using
GeneSpring GX V.13.0 (Agilent Technologies, Les Ulis,
France). The normality of log 2 ratio of gene expression
was evaluated using the Shapiro–Wilk statistical test.
The unpaired Student’s t test (p value < 0.05), with the
Benjamini–Hochberg correction to check the false
discovery rate (FDR), was used to determine the statis-
tical significance of differences in gene expression levels
between R and NR. Gene Ontology (GO) analysis was
used to investigate the biological processes, molecular
function or cellular localization enriched in the transcripts
list, showing a significant fluctuation in gene expression
between R and NR. The p value was computed by stand-
ard hypergeometric distribution. The GeneSpring Single
Experiment Analysis (SEA) bio-informatics tool was
used for computational analysis to identify potential cu-
rated canonical pathways with setting parameters (reac-
tome and GenMAPP for pathway source), which are
enriched in the differentially expressed transcripts list, using
the WikiPathways database (http://www.wikipathways.org/
index.php/Pathway:WP111). The significance of the associ-
ation between the genes and the pathways was measured
by Fisher’s exact test.
Results
Characteristics of patients with RA and their response to
ABA/MTX
Of the 104 patients with RA included in the original AP-
PRAISE trial, clinical and biological data for subsequent
analysis were available for 91 patients: 68 of these patients
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were recruited to this present ancillary study based on the
quality of the RNA samples (Fig. 1). These 68 patients
with RA were split into two subsets at random: subset 1
(n = 36) to identify clinical or biological (including tran-
scripts) markers associated with response to ABA/MTX
and subset 2 (n = 32) to validate a gene expression profile
able to predict good response to ABA/MTX (Fig. 1). After
6 months of treatment, patients with RA were categorized
according to their EULAR response as either responders
(R: n = 17 and 19, respectively in subsets 1 and 2) or non-
responders (NR: n = 19 and 13, respectively in subsets 1
and 2). Table 1 provides demographic and clinical infor-
mation for these 68 patients with RA at baseline and after
6 months of treatment.
Clinical and biological variables were collected before
treatment and 6 months later. Values are expressed as
mean ± standard error of the mean unless stated other-
wise. R responders, NR non-responders, F female, M male,
VAS visual analog scale, DAS Disease Activity Score in 28
joints, CRP C-reactive protein. Response to abatacept/
methotrexate was assessed by the DAS28 calculated with
CRP at 6 months of treatment. Patients were categorized
as indicated in “Methods”. P values were determined by
Student’s independent samples t test or paired t test as
appropriate: *p < 0.05; **p < 0.01 for comparisons between
responders and non-responders at baseline; $$$p < 0.001
for comparison of values at baseline and 6 months in re-
sponders; ££p < 0.01; £££p < 0.001 for comparison of values
at baseline and 6 months in non-responders. All other
comparisons were not significant.
The baseline characteristics of patients with RA from
subsets 1 and 2 were comparable for all variables, suggest-
ing absence of bias in randomization (Table 1). Whatever
the subset, tender joint count (TJC), swollen joint count,
global assessment of disease measured by the patient with
the VAS, CRP and DAS28(CRP) improved significantly
after 6 months of treatment in both R and in NR. How-
ever, the range of improvement was significantly higher in
R than in NR for each parameter except the global VAS
and CRP (Table 1 and Additional file 1). In each subset,
there were statistical differences between R and NR at
baseline in clinical and biological variables. Indeed, disease
duration was longer in NR than in R (p < 0.01) (Table 1).
DAS28, patient assessment of disease and CRP were
higher in NR than in R (p < 0.05). Moreover, the sex ratio
was significantly different between R and NR (p = 0.047).
There was better response in patients with RA of short
disease duration and moderate disease activity. These
observations raise the question of using clinical and bio-
logical variables as predictors of response.
Methotrexate/Abatacept treated RA patients
n=104
Clinical or biological
data missing
n=13
APPRAISE study
n=91
Poor quality samples
n=23
Good quality samples
(yield/RNA Integrity Number>7)
n=68
Randomization
Subset 1 «Discovery»
n=36
Response associated clinical/biological markers
Statistical approaches
Response associated bio-markers identification
Gene expression profiling
Subset 2 «Validation»
n=32
Prediction efficiency
Statistical approaches
Prediction efficiency
qRT-PCR
Minimal combination
Variables selection
Fig. 1 Ancillary study design from the APPRAISE trial. Of the 104 patients with rheumatoid arthritis (RA) enrolled in the APPRAISE trial, 68 were
included in our ancillary study after discarding patients with missing data or poor-quality RNA samples. Among these 68 patients with RA, two
subsets were designated, one for identification and one for validation. The first step of this ancillary study was to identify clinical parameters to
predict abatacept (ABA)/methotrexate (MTX) response. The second step was to identify a gene combination able to predict ABA/MTX response.
Subset 1, comprising 36 patients with RA, was used to identify clinical parameters or gene combinations to predict drug response. Subset 2, comprising
32 patients with RA, was used to validate these clinical parameters or gene combinations. qRT-PCR quantitative reverse-transcription PCR
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Clinical and biological variables are not associated with
response to ABA/MTX
Clinical and/or biological variables as predictors of response
were identified by two different multivariate statistical
approaches, logistic regression and linear discriminant ana-
lysis. Logistic regression based on more pertinent variables
as MTX, TJC, disease duration and CRP (identified in
subset 1) did not allow an accurate prediction of re-
sponse to ABA/MTX in subset 2 (sensitivity = 63%; speci-
ficity = 46%) (Fig. 2a). Similarly, linear discriminant
analysis, which balanced biological and clinical parame-
ters, did not allow accurate prediction of response to
ABA/MTX in subset 2 (sensitivity = 68%; specificity =
46%) (Fig. 2b). As a result of these shortcomings, we
used a microarray approach to identify biomarkers as-
sociated with response to ABA/MTX.
Gene expression profiling associated with response to
ABA/MTX
With subset 1, the cRNA from 17 R and 19 NR were
co-hybridized with a cRNA internal reference from 10
healthy subjects on whole human genome microarrays,
by two-color technology. After elimination of spikes
and flagged probes, 19,620 probes were detected in all
samples. From these 19,620 transcripts, we identified
87 transcripts with statistically significant variation be-
tween R and NR according to the t test with correction
for multiple testing (FDR, Benjamini–Hochberg correc-
tion) (Fig. 3a). These transcripts are listed in Additional
file 2 (69 transcripts are referenced with a Ref Seq ac-
cession number while 18 probes were unknown). Since
the sex ratio in R and in NR was significantly different,
this maldistribution between male and female patients
did not introduce bias into our study (data not shown)
Finally, we performed hierarchical clustering of the 36
patients from subset 1 based on the levels of the 87
transcripts indicated previously, resulting in almost
perfect separation of R and NR into two major clusters.
Indeed, only one R patient was misclassified in the pa-
tient’s dendrogram (Fig. 3b).
We wanted to confirm that a combination of the afore-
mentioned transcript levels was associated with response
A B
Fig. 2 Inability of clinical and biological parameters to predict response to abatacept/methotrexate (ABA/MTX). Two independent statistical
methods were performed to identify variables to predict drug response in subset 1. Next, the prediction accuracy of these variables was evaluated in
subset 2. a In subset 1, four variables were selected by logistic regression: C-reactive protein (CRP), tender joint count, MTX dose and disease duration.
In subset 2, these four variables allowed good categorization of 12 out of 19 responders (R) and 6 out of 13 non-responders (NR). The remaining 14
patients were misclassified. b In subset 1, linear discriminant analysis was performed to balance each parameter by calculation of the coefficient of
linear discriminant analysis. In subset 2, these data allowed good categorization of 13 out of 19 R and 6 out of 13 NR. The remaining 13 patients were
misclassified. DAS28 disease activity score in 28 joints, Sen sensitivity, Spe specificity, PPV positive predictive value, NPV negative predictive value
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Table 2 Gene ontology (GO) analysis with the 87 transcripts dysregulated between responders and non-responders to abatacept/
methotrexate
GO accession GO term P value Count in 87
mRNA list
Percentage in
87 mRNA list
Count in
human
genome
Percentage
in human
genome
Enrichment
Biological process
GO:1902600 Hydrogen ion transmembrane transport 0.0011 6 10.17 93 0.55 18.38
GO:0022904 Respiratory electron transport chain 0.0011 6 10.17 99 0.59 17.26
GO:0022900 Electron transport chain 0.0011 6 10.17 101 0.60 16.92
GO:0045333 Cellular respiration 0.0011 7 11.86 146 0.87 13.66
GO:0015992 Proton transport 0.0019 6 10.17 115 0.68 14.86
GO:0006818 Hydrogen transport 0.0019 6 10.17 117 0.70 14.61
Molecular function
GO:0015002 Heme-copper terminal oxidase activity 0.0011 4 6.78 23 0.14 49.54
GO:0004129 Cytochrome-c oxidase activity 0.0011 4 6.78 23 0.14 49.54
GO:0016676 Oxidoreductase activity, acting on a heme
group of donors, oxygen as acceptor
0.0011 4 6.78 23 0.14 49.54
GO:0016675 Oxidoreductase activity, acting on a heme
group of donors
0.0011 4 6.78 24 0.14 47.47
GO:0015078 Hydrogen ion transmembrane transporter
activity
0.0011 6 10.17 88 0.52 19.42
Cellular localization
GO:0070469 Respiratory chain 0.0011 6 10.17 68 0.40 25.13
GO:0044455 Mitochondrial membrane part 0.0011 7 11.86 144 0.86 13.85
GO:0005743 Mitochondrial inner membrane 0.0011 10 16.95 350 2.08 8.14
GO:0019866 Organelle inner membrane 0.0011 10 16.95 390 2.32 7.30
GO:0005746 Mitochondrial respiratory chain 0.0017 5 8.47 62 0.37 22.97
GO:0005740 Mitochondrial envelope 0.0017 11 18.64 544 3.24 5.76
GO:0031966 Mitochondrial membrane 0.0053 10 16.95 508 3.02 5.61
Corrected p values were determined by a standard hypergeometric distribution
Log2(FC)
-
(01gol
eulav
Prroc
)
A B
Log2(FC)
NR
R
Fig. 3 Gene expression profiling associated with response to abatacept/methotrexate in subset 1. Baseline samples from subset 1 (n= 36 (17 responders
(R) and 19 non-responders (NR)) were hybridized on 4 × 44 K whole human genome microarrays. a The t test with the Benjamini–Hochberg correction for
estimation of the false discovery rate (p< 0.05) was used to identify 87 transcripts (red dots) with dysregulation that was associated with response (R vs NR).
b Hierarchical clustering: Pearson coefficient and complete linkage metrics were used to obtain the transcripts and sample dendrograms. Fold change (FC)
is the ratio of relative abundance of transcripts in patients with rheumatoid arthritis vs control pool
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to ABA/MTX. For this purpose, we used linear discrim-
inant analysis to select a minimal combination of tran-
scripts from “identification” subset 1 that were able to
correctly classify patients with RA from “validation”
subset 2. Among these 87 mRNA, four transcripts
(BLOC1S1, RNASE3, COX6A1, PTRH2) were retained
by linear discriminant analysis although they did not
have the smallest p value (Table 2). As shown in Fig. 4,
hierarchical clustering of the 32 patients from subset 2,
based on the levels of these four transcripts measured
by qRT-PCR, resulted in two major clusters of R versus
NR, with 26 well-categorized patients. This procedure
identified six misclassified patients and indicated that
this set of four transcripts provides 75% sensitivity, 85%
specificity, and 85% negative predictive value and 75%
positive predictive value for identification of future R
and NR to ABA/MTX. To ascertain if this signature
was specific to ABA, we used this combination of 87
mRNA associated with drug response in an independ-
ent cohort of patients with RA, with the same level of
disease activity, treated by TNFα blocking agents given
as etanercept or adalimumab (Additional file 3), both asso-
ciated with MTX. This combination was unable to correctly
classify R and NR to TNFα blocking agents whatever the
molecular structure (fusion protein or monoclonal antibody
directed against TNFα), suggesting specificity of this signa-
ture for ABA/MTX (Additional file 3). This combination of
87 transcripts also raised the question of understanding the
biological significance of these genes in response to ABA/
MTX in the pathophysiology of RA.
Pre-silencing of electron transport chain pathway
associated with response to ABA/MTX
Different approaches were used to understand the in-
volvement of this 87 mRNA signature in biological
processes. These 87 mRNA were submitted to GO ana-
lysis leading us to discover enrichment (from 6 to 49
times more) of 18 GO classes in these 87 mRNA com-
pared to the whole human genome (Table 2). Among
these 87 transcripts, 11 were associated with these 18
GO classes (Additional file 4).
All these 18 GO classes, based on the 87 mRNA, were
relative to the mitochondrial respiratory chain located in
the inner membrane of mitochondria (corrected p value
<0.005). For instance, 6/87 mRNA of genes linked to the
electron transport chain (ETC; GO: 0022900) were in-
cluded in our signature while 101 genes from the whole
human genome are known to be relative to this same
GO class (corrected p value = 0.001). The fold enrich-
ment in this GO term is × 16 (Table 2). Moreover, these
87 mRNA were submitted to WikiPathways using the
SEA tool from GeneSpring software leading us to identify
enrichment of four signaling pathways: Electron Transport
Chain WP111_41171 (version of 1 March 2011; p value =
1.6.10-9), Oxidative Phosphorylation WP623_45305 (ver-
sion of 7 October 2011; p value = 2.5.10-4), Proteasome
Degradation WP183_45274 (version of 7 October 2011;
p value = 0.008) and TSH signaling pathway WP2032_44635
(version of 22 September 2011 ; p value = 0.008). GO ana-
lysis and SEA were in agreement as the ETC pathway local-
ized in mitochondria was found by using these two tools.
As shown in Fig. 5a, the ETC pathway includes 104
proteins split up into five complexes of ETC, embedded
in the inner membrane of mitochondria. Among the 87
mRNA of our signature, 7 transcripts from the ETC
pathway (NDUFA6, NDUFA4, UQCRQ, ATP5J, COX7A2,
COX7B, COX6A1) covering four out of five complexes of
this pathway, were significantly (p value <0.05) downregu-
lated in 17 R versus 19 NR to ABA/MTX (Fig. 5a and b).
This differential gene expression profile including these
RNASE3
BLOC1S1
COX6A1
PTRH2
R NR
NR
R
Log2(transcript/HK)
Fig. 4 Validation of a small transcript combination associated with response to abatacept/methotrexate (ABA/MTX) in subset 2. A minimal
combination of four transcripts (RNASE3, BLOC1S1, COX6A1, PTRH2) was identified by logistic regression from the 87 transcripts previously identified
with subset 1. Next, the ability of these four transcripts to predict ABA/MTX response was evaluated by quantitative reverse-transcription (qRT)-PCR
with subset-2 samples. Hierarchical clustering based on normalized qRT-PCR values was built with the Pearson coefficient metric and complete linkage.
These data allowed good categorization of 16 out of 19 responders (R) and 10 out of 13 non-responders (NR), for a total of 26 among the 32 patients
with RA overall in subset 2. Intensity values were expressed as an expression ratio (transcript/housekeeping (HK) gene)
Derambure et al. Arthritis Research & Therapy  (2017) 19:109 Page 8 of 13
seven genes suggested reduced expression of the mito-
chondrial respiratory chain pathway in R before ABA
administration (Fig. 5b). In addition, taking into account
gene expression profiling from the whole ETC pathway
(n = 104 genes), principal component analysis correctly
separated R from NR before treatment, even if all the
transcripts from this pathway were not significantly
dysregulated between R and NR (Fig. 5c). Nevertheless,
this ETC combination including these 104 transcripts
did not better separate R and NR (73% specificity) than
did the minimal combination of four transcripts (85%
specificity) (Fig. 4).
The dysregulation of these transcripts could be linked
to the more elevated CRP rate observed in NR compared
to R at baseline (Table 1). Correlations between each
significant transcript level from the ETC pathway
(NDUFA6, NDUFA4, UQCRQ, ATP5J, COX7A2, COX7B,
COX6A1) and CRP or DAS28(CRP) were performed to
discard a CRP or disease activity effect on the gene
expression levels from this signature linked to a sup-
posedly more pronounced mitochondrial activity in the
inflammatory state. A weak positive coefficient of correl-
ation (r) and coefficient of determination (r2) between
CRP (0.25 < r < 0.49; 0.06 < r2 < 0.24) or DAS28(CRP)
A
C
R
NR
)
C
F(2goL
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
2.5
NDUFA6
NDUFA4
UQCRQ
ATP5J
COX7A2
COX7B
COX6A1
B
NRR
Fig. 5 Pre-silencing of mitochondrial respiratory chain associated with abatacept/methotrexate (ABA/MTX) response. a Electron transport chain (ETC)
WP111-41171 WikiPathway (http://www.wikipathways.org/index.php/Pathway:WP111). In the 87 mRNA dysregulated between responders (R) and non-
responders (NR) to ABA/MTX, there was highly significant enrichment of mRNA involved in ETC (p value = 1.6.10-9). The p value was deter-
mined by standard hypergeometric distribution. This enrichment involved 7 mRNA from the 87 transcripts, which are highlighted in yellow
among the 104 proteins from the whole ETC pathway. b Gene expression level expressed as fold change (FC) (patients with RA/control pool)
for these 7 mRNA in 17 R and 19 NR. c Principal component analysis of 17 R and 19 NR performed with gene expression level (fold change) of the 104
mRNA from the whole ETC pathway. Component 1: 40.3%; component 2: 16.7%
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(0.32 < r < 0.43; 0.10 < r2 < 0.18) and gene expression level
was observed for the majority of genes except ATP5J. In
subset 2, weak positive correlation between CRP or
DAS28(CRP) and gene expression data was also found
for NDUFA4, COX6A1, COX7A2 and COX7B (data not
shown). All these data led us to discard the impact of
CRP or disease activity on the dysregulation of the ETC
pathway between R and NR at baseline (Additional file 5).
Finally, we measured gene expression fluctuation in an
independent transcriptomic analysis between baseline
and 6 months of treatment by ABA/MTX in R and NR.
Only five genes (COX7B, COX11, UQCRC2, NDUFU3,
NDUFS1) among the 104 genes involved in the ETC
pathway were significantly upregulated in R after
6 months of treatment, while these genes were invariant
in NR to ABA/MTX (data not shown). This observation
suggests that ABA increased gene expression levels of
some genes from the ETC pathway only in R and not in
NR independently of disease activity, which decreased
whatever the response to ABA/MTX. Overall, these re-
sults suggest that these gene levels were not related to
disease but rather they are genes of susceptibility to
ABA and that silent expression of the ETC signature is
associated more with good response to ABA/MTX.
Discussion
In this ancillary study, we identified 87 transcripts with
relative abundances, which were able to separate R and
NR to ABA/MTX in 36 patients with RA before treatment
(Fig. 3 and Additional file 2). Next, for the first time we
validated a minimal combination of four transcripts asso-
ciated with response to ABA/MTX in an independent
subset of 32 patients with RA (Fig. 4). According to GO
and WikiPathways analysis, we identified enrichment of 7
genes among the aforementioned 87 belonging to the
ETC pathway, suggesting a specific signature of response
(Fig. 5). Indeed, patients with RA with pre-silencing of the
ETC pathway before treatment were those most suscep-
tible to responding to ABA/MTX 6 months later.
In the current context of personalized medicine for the
management of RA, the optimization of drug prescription
is crucial. Hence, drug prescription should be tailored ex-
clusively only to patients susceptible to responding to the
drug. The identification of biomarkers to predict of drug
response is paramount. To date, there are only two bio-
markers associated with good response to ABA/MTX in
RA, anti-CCP positivity and low baseline number of CD8
+CD28– T cells [27–30]. Furthermore, there is no clinical
and/or biological biomarker used in routine practice able
to predict response to ABA/MTX prior to treatment initi-
ation. Indeed, in our study, two statistical approaches to
multivariate analysis were unable to identify predictive
clinical or biological parameters of response to ABA/
MTX, even if disease duration, CRP, global patient
assessment of disease and DAS28(CRP) were signifi-
cantly different between R and NR at baseline (Table 1
and Fig. 2). It would be interesting to establish a rela-
tionship between response to ABA and anti-
citrullinated protein antibodies (ACPA) and/or rheuma-
toid factor status, given that ACPA positivity is associ-
ated with better response to ABA in RA. Unfortunately,
we were unable to include ACPA or rheumatoid factor
status in our analysis because these data were not col-
lected during the APPRAISE trial and were not avail-
able. The difficulties we faced in predicting drug
response with clinical and/or biological variables led us
to use a more global functional genomic approach
without a priori having to identify a signature associ-
ated with good response to ABA/MTX.
The transcriptomic approach based on the whole
genome allowed us to identify signatures able to separ-
ate R from NR to several drugs (infliximab, tocilizumab,
rituximab) used in RA [17–21, 31]. For ABA, one study
previously measured the type-I interferon-regulated
transcripts from peripheral blood mononuclear cells in
patients with RA, independently of response to ABA
[32]. Another study identified gene sets associated with
remission according to clinical disease activity index
(CDAI) in ABA-treated patients with RA [33]. In our
study, even if there were differences at baseline in dis-
ease duration, CRP, patient assessment of disease and
DAS28(CRP) between R and NR, which might have in-
fluenced gene expression, we identified and validated a
gene signature associated with response to ABA/MTX.
This signature included 87 genes variously involved in
the ETC, proteasome, interferon and RNA processes,
etc. This combination of 87 genes is also specific to
ABA as it was not able to predict TNFα blocking agent
response. Next, we validated this signature with an in-
dependent subset of 32 patients with RA by means of a
minimal combination of four genes with expression
levels measured by qRT-PCR, which are more easily us-
able in routine practice than microarrays. This signa-
ture is the optimized combination of genes associated
with drug response with good accuracy, because it cor-
rectly predicted the future response in 81% of patients
with RA (75% sensitivity, 85% specificity, 85% negative
predictive value and 75% positive predictive value) prior
to treatment (Fig. 4). Each gene taken separately was
unable to predict response to ABA/MTX (data not
shown) but all genes together were associated with re-
sponse to ABA/MTX with good accuracy. Nevertheless,
further validation studies in independent cohorts are
essential before considering this signature as a predict-
ive biomarker and of use in clinical practice.
Of the four genes in the minimal combination, the
RNAseIII gene codes for the RNAseIII enzyme that specif-
ically cleaves double-stranded RNA and is involved in the
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processing of ribosomal RNA precursors of some mRNAs
[34]. Biogenesis of lysosomal organelles complex-1, sub-
unit 1 (BLOC1S1) codes for the protein BLOC1S1, also
known as GCN5L1, and is an essential component of the
mitochondrial acetyltransferase machinery and modulates
mitochondrial respiration via acetylation of ETC proteins
[35]. COX6A1 codes for the mitochondrial protein cyto-
chrome c oxidase subunit 6A1 (COX6A1) located in
complex IV. This is the last enzyme in the mitochondrial
ETC that drives ATP synthesis [36]. PTRH2 codes for the
peptidyl-tRNA hydrolase 2, which is a mitochondrial pro-
tein released from mitochondria to the cytoplasm during
apoptosis.
Out of these 4 transcripts, 3 (BLOC1S1, COX6A1 and
PTRH2) and 13 probes out of 87 code for proteins located
in mitochondria. In addition, some of them are involved
in the ETC pathway, suggesting implication of mitochon-
drial metabolism in response to ABA/MTX. Moreover,
GO analysis and SEA are in agreement as these two ana-
lyses point to the involvement of ETC in the response to
ABA/MTX. Interestingly, we found that seven transcripts
with levels that are significantly lower in R than in NR at
baseline were similarly regulated in patients in remission
and patients not in remission defined by clinical disease
activity index (CDAI) in a recent study [33]. The ETC is a
series of five complexes anchored to the inner membrane
of mitochondria that transfers electrons via redox reac-
tions, which drives ATP synthesis, generating reactive oxy-
gen species (ROS) and subsequent oxidative stress [37].
Redox balance in mitochondria is a critical component in
T cell activation and proliferation [38]. The production of
ROS by the ETC complex III leads to production of large
amounts of ATP to enhance activity of proliferating T cells
after TCR cross-linking [39–42]. In our study, ETC genes
were downregulated in R compared to NR, suggesting po-
tentially low ROS production and potentially less T cell ac-
tivation before treatment. Also, a previous study suggested
it would be interesting to determine whether ROS produc-
tion in T cells might be a predictor of clinical response to
ABA [43]. Our results suggest the possible involvement of
ROS in the pathophysiological processes of ABA response,
but further functional studies are necessary to confirm this
hypothesis.
This 87 mRNA signature also included RASSF5, which
was significantly upregulated in R compared to NR.
RASSF5, also known as RAPL, is the effector of Rap1,
which plays a central role in T cell response through TCR
and co-stimulation signals. Indeed, a model was proposed
in which inactivation of Rap1 plays a central role in estab-
lishing oxidative stress and can influence T cell response
in RA [43, 44]. These data suggest less oxidative stress in
future responders to ABA while NR present with high ex-
pression of genes from the ETC pathway, showing oxida-
tive stress. A reduction in the expression level of ETC
genes seems to increase the sensitivity of patients with RA
to ABA/MTX. This model has already been highlighted in
esophageal adenocarcinoma and colorectal cancer treated
by chemotherapy [45, 46]. Indeed, ATP5J and COX7A2 in-
cluded in our combination were also found to be down-
regulated and associated with response to chemotherapy,
respectively in colorectal cancer and esophageal adenocar-
cinoma [45, 46]. As in cancer, pre-treatment conditions
targeting the mitochondrial metabolism might be a deter-
minant of susceptibility to ABA/MTX [47].
After 6 months of treatment with ABA, we showed
that five genes (COX7B, COX11, UQCRC2, NDUFU3,
NDUFS1) involved in the ETC pathway were signifi-
cantly upregulated in R, while these genes were invariant
in NR to ABA/MTX. So, whereas ABA does not seem to
affect the oxidative state in NR, it seems to modulate oxi-
dative stress in R, as genes from the ETC pathway were
upregulated under ABA. This drug restores the expression
of genes involved in redox balance.
Conclusions
In summary, we identified and validated a gene expression
signature associated with good response to ABA/MTX.
This signature involves genes from the ETC pathway. The
pre-silencing of these genes could be a specific determin-
ant of susceptibility to MTX +ABA. The downregulation
of these genes reflected the redox imbalance observed in
R. The intracellular redox balance is crucial for the anti-
genic response of T cells. After 6 months of treatment,
ABA significantly upregulated some ETC genes in R prob-
ably leading to a slight increase in ROS, restoring the
redox balance and improving T cell response. Further
studies, including the investigation of ROS levels in R and
NR to ABA/MTX, are necessary for large-scale validation
of this signature before evaluating its pertinence in clinical
practice.
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